10.1001/jamainternmed.2021.5511

10.31234/osf.io/247bs

10.1073/pnas.2021636118

10.1038/s41590-021-01049-2

10.1016/j.jesp.2021.104184

10.1038/s41562-021-01173-x

10.1136/bmj.n2452

10.1016/j.paid.2021.111295

10.31234/osf.io/83m9y

10.1057/s41599-019-0279-9

10.1016/S0140-6736(17)31226-6

10.1016/j.socscimed.2019.06.002

10.1016/S2468-2667(20)30010-4

10.1136/bmj.l1161

10.1080/21645515.2018.1522468

10.5964/jspp.v8i2.1362

10.2105/AJPH.2018.304661

10.5334/joc.91

10.1371/journal.pone.0175799

10.1080/10410236.2017.1331312

10.1126/science.abj9853 PREVIOUS ARTICLEA priori control of zeolite phase competition and intergrowth with high-throughput simulationsPreviousNEXT ARTICLEA year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in AfricaNext

10.1038/s41576-021-00408-x

doi: https://doi.org/10.1038/d41586-021-02383-z

doi: https://doi.org/10.1038/d41586-021-02483-w

10.3389/fpos.2021.661257

10.3389/fimmu.2021.558270

10.1002/ejsp.2796

10.1126/sciadv.abd1705

10.15585/mmwr.mm6937e4

10.3389/fcomm.2021.721982

10.1016/S0140-6736(21)00628-0

10.1038/s41591-021-01449-9

10.1038/s41586-021-03792-w

10.31234/osf.io/csfte

10.1007/s42001-020-00086-5

10.1136/bmj.n26

10.3390/fi12120210

10.1080/13642529.2021.1934290

10.31234/osf.io/hu9ef

10.1136/bmj.n1686

10.31478/202107a

10.1038/s41591-021-01433-3

10.3201/eid2702.203139

10.1056/NEJMoa2109072

10.1016/j.immuni.2021.06.012

10.3389/fpsyg.2020.566790

10.1016/j.immuni.2021.06.006

10.1001/jama.2020.4469

10.1002/poi3.214

10.1038/s41562-020-0889-7

10.1177/1075547017731776

10.3389/fpubh.2021.716333

10.1136/thoraxjnl-2021-217080

10.1136/bmj.n1931

Objective To assess the association between covid-19 vaccines and risk of thrombocytopenia and thromboembolic events in England among adults.Design Self-controlled case series study using national data on covid-19 vaccination and hospital admissions.Setting Patient level data were obtained for approximately 30 million people vaccinated in England between 1 December 2020 and 24 April 2021. Electronic health records were linked with death data from the Office for National Statistics, SARS-CoV-2 positive test data, and hospital admission data from the United Kingdom’s health service (NHS).Participants 29 121 633 people were vaccinated with first doses (19 608 008 with Oxford-AstraZeneca (ChAdOx1 nCoV-19) and 9 513 625 with Pfizer-BioNTech (BNT162b2 mRNA)) and 1 758 095 people had a positive SARS-CoV-2 test. People aged ≥16 years who had first doses of the ChAdOx1 nCoV-19 or BNT162b2 mRNA vaccines and any outcome of interest were included in the study.Main outcome measures The primary outcomes were hospital admission or death associated with thrombocytopenia, venous thromboembolism, and arterial thromboembolism within 28 days of three exposures: first dose of the ChAdOx1 nCoV-19 vaccine; first dose of the BNT162b2 mRNA vaccine; and a SARS-CoV-2 positive test. Secondary outcomes were subsets of the primary outcomes: cerebral venous sinus thrombosis (CVST), ischaemic stroke, myocardial infarction, and other rare arterial thrombotic events.Results The study found increased risk of thrombocytopenia after ChAdOx1 nCoV-19 vaccination (incidence rate ratio 1.33, 95% confidence interval 1.19 to 1.47 at 8-14 days) and after a positive SARS-CoV-2 test (5.27, 4.34 to 6.40 at 8-14 days); increased risk of venous thromboembolism after ChAdOx1 nCoV-19 vaccination (1.10, 1.02 to 1.18 at 8-14 days) and after SARS-CoV-2 infection (13.86, 12.76 to 15.05 at 8-14 days); and increased risk of arterial thromboembolism after BNT162b2 mRNA vaccination (1.06, 1.01 to 1.10 at 15-21 days) and after SARS-CoV-2 infection (2.02, 1.82 to 2.24 at 15-21 days). Secondary analyses found increased risk of CVST after ChAdOx1 nCoV-19 vaccination (4.01, 2.08 to 7.71 at 8-14 days), after BNT162b2 mRNA vaccination (3.58, 1.39 to 9.27 at 15-21 days), and after a positive SARS-CoV-2 test; increased risk of ischaemic stroke after BNT162b2 mRNA vaccination (1.12, 1.04 to 1.20 at 15-21 days) and after a positive SARS-CoV-2 test; and increased risk of other rare arterial thrombotic events after ChAdOx1 nCoV-19 vaccination (1.21, 1.02 to 1.43 at 8-14 days) and after a positive SARS-CoV-2 test.Conclusion Increased risks of haematological and vascular events that led to hospital admission or death were observed for short time intervals after first doses of the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines. The risks of most of these events were substantially higher and more prolonged after SARS-CoV-2 infection than after vaccination in the same population.

10.1101/2021.09.17.21263549

10.31234/osf.io/psuwq

10.31234/osf.io/xwtmy

10.31234/osf.io/65qfj

10.31234/osf.io/6s4vf

10.31234/osf.io/nqjb9

10.1101/2021.09.28.21264260

10.31234/osf.io/dah3x

10.31234/osf.io/fsnvy

10.31234/osf.io/m7w9y

10.31234/osf.io/6gjh8

/10.1080/17538068.2016.1235531

 10.1371/journal.pone.0210746

10.1136/bmj.c5347

10.1371/journal.pone.0181368

10.1007/s10339-019-00919-w

10.1136/bmj.n2357

10.1016/j.jvacx.2021.100114

10.7326/M21-2721

10.31234/osf.io/kdr6u

10.31234/osf.io/ebw4g

10.1098/rsos.201199

10.1016/j.vaccine.2020.07.054

10.1371/journal.pone.0181640

10.1016/j.shpsa.2021.08.018

10.31234/osf.io/4ef7m

10.1136/bmj.n2165

10.1073/pnas.2101386118

10.31234/osf.io/fdyxr

10.1093/infdis/jiz024

10.1177/2333721419870345

10.31234/osf.io/8jver

10.31234/osf.io/cpxry

10.1136/bmj.n2306

10.1136/bmj.n2297

10.1136/bmj.n2244

10.1136/bmj.n2168

10.1038/s41587-021-01020-4

doi: https://doi.org/10.1136/bmj.n2211

doi: https://doi.org/10.1038/d41586-021-02516-4

10.31234/osf.io/z6kxm

10.1016/S0140-6736(21)02046-8

10.1136/bmj.n2251

10.1038/s43856-021-00027-x

10.3389/fpsyg.2021.701255

10.3389/fpsyg.2021.721716

10.3389/fpsyg.2021.681975

10.1140/epjds/s13688-021-00301-x

10.31234/osf.io/6cu3t

10.1103/PhysRevE.104.034303

10.15585/mmwr.mm7037e3external icon.

10.3389/fpsyg.2021.642616

10.3389/fpsyg.2021.644212

10.3389/fpsyg.2021.714397

10.3389/fpsyg.2021.676116

10.1101/2021.09.03.21263086

10.31234/osf.io/v9gax

10.31234/osf.io/fcyqd

10.31234/osf.io/m8dbc

10.31234/osf.io/8jsr3

10.31234/osf.io/6j38h

10.1016/S1473-3099(21)00474-6

10.1016/S1473-3099(21)00475-8

10.1073/pnas.2109229118

10.3389/fpsyg.2021.696132

10.1126/sciimmunol.abl4509 PREVIOUS ARTICLEA reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing anti-tumor immune responsePreviousNEXT ARTICLECross-reactive antibodies against human coronaviruses and the animal coronavirome suggest diagnostics for future zoonotic spilloversNext Data is empty

10.1056/NEJMoa2110475